Jefferies Starts ALX Oncology (ALXO) at Buy

Jefferies analyst Roger Song initiates coverage on ALX Oncology (NASDAQ: ALXO) with a Buy rating and a price target of $4.00.

The analyst comments "ALXO has strategically focused on two lead programs: 1) ASPEN-09: Evorpacept (CD47 blocker) in post-ENHERTU HER2⁺ mBC using prospective CD47 enrichment, supported by encouraging gastric data w/ Ph2 interim data 3Q26 to inform pivotal plan 2) ALX2004: an EGFR-targeted Topo-I ADC w/ differentiated design for wider therapeutic window in solid tumors currently enrolling 2nd Ph1 dose arm w/ safety update 1H26 guiding next steps. We initiate at BUY rating with PT $4."

For an analyst ratings summary and ratings history on ALX Oncology click here. For more ratings news on ALX Oncology click here.

Shares of ALX Oncology closed at $1.28 yesterday.

You May Also Be Interested In

• IBM (IBM) PT Lowered to $280 at BofA Securities
• ServiceNow (NOW) PT Raised to $115 at UBS as Demand Trends Appear Stable
• Antero Resources (AR) PT Lowered to $50 at UBS